Rapid Readouts: Initial Results of the Phase III BOSTON Study

Rolling Submission to FDA Completed for Cilta-Cel for Relapsed/Refractory Multiple Myeloma

FDA Approval Sought for Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell ALL

Third-Line CAR T-Cell Therapy Improves Outcomes in B-Cell Lymphomas